Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.52 |
| ▸ | SPR | P35270 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282433 | 0.91 | NAMPT (0.60) | PDE4BHSD11B1NAMPTSPRLMNA | |
| SCHEMBL17037455 | 0.89 | HSD11B1 (0.51) | PDE4BHSD11B1NAMPTSPRLMNA | |
| SCHEMBL16886312 | 0.85 | RAB9A (0.58) | PDE4BHSD11B1NAMPTLMNANPC1 | |
| SCHEMBL16886321 | 0.83 | HSD11B1 (0.57) | PDE4BHSD11B1NAMPTSPRLMNA | |
| SCHEMBL14276847 | 0.83 | HSD11B1 (0.56) | PDE4BHSD11B1NAMPTSPRLMNA | |
| SCHEMBL2807714 | 0.81 | HSD11B1 (0.58) | HSD11B1NAMPTSPRLMNACYP2C9 | |
| SCHEMBL20149063 | 0.80 | HSD11B1 (0.60) | HSD11B1NAMPTSPRLMNACYP2C9 | |
| SCHEMBL14413518 | 0.80 | HSD11B1 (0.56) | PDE4BHSD11B1NAMPTSPRLMNA | |
| SCHEMBL16600285 | 0.80 | HSD11B1 (0.56) | HSD11B1NAMPTSPRLMNACYP2C9 | |
| SCHEMBL17516279 | 0.80 | PDE4B (0.53) | PDE4BNAMPTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC | 2019-01-24 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | PDE4B 1552/4885HSD11B1 1230/4885NAMPT 3260/4885 |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | PDE4B 1430/4885HSD11B1 3248/4885NAMPT 2637/4885 |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | PDE4B 1430/4885HSD11B1 3248/4885NAMPT 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.